Patents by Inventor Paolo B. Abada

Paolo B. Abada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-VEGFR2 antibody therapy for hepatocellular carcinoma
    Patent number: 10766961
    Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: September 8, 2020
    Assignee: ImClone LLC
    Inventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
  • ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA
    Publication number: 20170226212
    Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma in patients having levels of alpha-fetoprotein (AFP) of 1.5 ULN or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 10, 2017
    Applicant: IMCLONE, LLC
    Inventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang